Eliana Merle
Stock Analyst at UBS
(2.05)
# 2,833
Out of 4,711 analysts
66
Total ratings
31.91%
Success rate
-0.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMT Sagimet Biosciences | Initiates: Buy | $12 | $4.95 | +142.42% | 1 | Nov 12, 2024 | |
| IVA Inventiva | Initiates: Neutral | $3 | $2.35 | +27.66% | 1 | Nov 12, 2024 | |
| ALT Altimmune | Initiates: Buy | $26 | $8.25 | +215.15% | 1 | Nov 12, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $74 | $40.66 | +82.00% | 2 | Nov 4, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $411 → $441 | $308.44 | +42.98% | 3 | Nov 1, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $104 → $106 | $65.66 | +61.44% | 1 | Oct 30, 2024 | |
| ANAB AnaptysBio | Maintains: Neutral | $23 → $33 | $14.55 | +126.80% | 4 | Oct 30, 2024 | |
| MRNA Moderna | Maintains: Buy | $140 → $108 | $39.39 | +174.18% | 4 | Oct 24, 2024 | |
| BNTX BioNTech SE | Maintains: Neutral | $97 → $131 | $113.08 | +15.85% | 6 | Sep 18, 2024 | |
| RAPT RAPT Therapeutics | Maintains: Neutral | $10 → $2 | $0.83 | +142.31% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $83 | $33.21 | +149.92% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $253 → $288 | $245.44 | +17.34% | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $3.00 | +66.67% | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $26.49 | +77.43% | 2 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $8.65 | -42.20% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $5.86 | +207.17% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $42 | $29.34 | +43.15% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $44.06 | -9.21% | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $25 | $7.94 | +214.86% | 2 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $16.98 | +147.35% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $18 | $2.87 | +527.18% | 1 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $8 | $0.84 | +852.38% | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $6.93 | +217.46% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $7.62 | +516.80% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $9.80 | +63.27% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $123 | $18.48 | +565.58% | 3 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $26.76 | +400.75% | 3 | Aug 19, 2020 |
Sagimet Biosciences
Nov 12, 2024
Initiates: Buy
Price Target: $12
Current: $4.95
Upside: +142.42%
Inventiva
Nov 12, 2024
Initiates: Neutral
Price Target: $3
Current: $2.35
Upside: +27.66%
Altimmune
Nov 12, 2024
Initiates: Buy
Price Target: $26
Current: $8.25
Upside: +215.15%
Kymera Therapeutics
Nov 4, 2024
Maintains: Buy
Price Target: $80 → $74
Current: $40.66
Upside: +82.00%
Madrigal Pharmaceuticals
Nov 1, 2024
Maintains: Buy
Price Target: $411 → $441
Current: $308.44
Upside: +42.98%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Buy
Price Target: $104 → $106
Current: $65.66
Upside: +61.44%
AnaptysBio
Oct 30, 2024
Maintains: Neutral
Price Target: $23 → $33
Current: $14.55
Upside: +126.80%
Moderna
Oct 24, 2024
Maintains: Buy
Price Target: $140 → $108
Current: $39.39
Upside: +174.18%
BioNTech SE
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $113.08
Upside: +15.85%
RAPT Therapeutics
Sep 9, 2024
Maintains: Neutral
Price Target: $10 → $2
Current: $0.83
Upside: +142.31%
Aug 9, 2024
Maintains: Buy
Price Target: $85 → $83
Current: $33.21
Upside: +149.92%
Jun 28, 2024
Maintains: Buy
Price Target: $253 → $288
Current: $245.44
Upside: +17.34%
Jun 20, 2024
Downgrades: Neutral
Price Target: $28 → $5
Current: $3.00
Upside: +66.67%
May 28, 2024
Maintains: Buy
Price Target: $51 → $47
Current: $26.49
Upside: +77.43%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $8.65
Upside: -42.20%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $5.86
Upside: +207.17%
Mar 5, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $29.34
Upside: +43.15%
Dec 20, 2023
Initiates: Buy
Price Target: $40
Current: $44.06
Upside: -9.21%
Oct 12, 2023
Maintains: Buy
Price Target: $36 → $25
Current: $7.94
Upside: +214.86%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $16.98
Upside: +147.35%
Jan 19, 2023
Upgrades: Buy
Price Target: $18
Current: $2.87
Upside: +527.18%
Dec 7, 2022
Maintains: Buy
Price Target: $19 → $8
Current: $0.84
Upside: +852.38%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $6.93
Upside: +217.46%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $7.62
Upside: +516.80%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $9.80
Upside: +63.27%
May 21, 2021
Initiates: Buy
Price Target: $123
Current: $18.48
Upside: +565.58%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $26.76
Upside: +400.75%